HOME
RESOURCES
MEMBERS
EVENTS
PATIENTS
NEWS
ABOUT
Overview
Quality Initiatives
Join
Health Equity
Team
Contact Us
Past Events
SPECIALTY CARE
Nephrology
MY RESOURCES
Point of Care Tools
My Bookmarks
ADMIN PORTAL
PATIENT DATA DASHBOARD
NEWS

ABOUT

OverviewQuality InitiativesJoinHealth EquityTeamContact UsPast Events

SPECIALTY CARE

Nephrology

MY RESOURCES

Point of Care ToolsMy Bookmarks
ADMIN PORTAL
PATIENT DATA DASHBOARD
MCT2D Logo
RESOURCESMEMBERSEVENTSPATIENTS
Search Icon

MCT2D Resource: Dosing Information for SGLT-2 Inhibitors and GLP-1 Receptor Agonists for Type 2 Diabetes

DOWNLOAD RESOURCELINK TO RESOURCE

Updated: 10/16/23

Key dosing information for SGLT2-I and GLP1-RAs including dose escalation, pen and needle RX considerations, proven benefits for ASCVD, CKD, HFrEF, HFpEF, and DKD.

Tags: For Providers, Created By MCT2D, Point-of-care

MCT2D Newsletter

Subscribe to the MCT2D Newsletter

Once per month we deliver news, updates, events, and more directly to you!

ccteam@mct2d.org

ResourcesPoint of CareMy BookmarksMembersEventsNewsPatientsSpecialty CareNephrology
AboutOverviewQuality InitiativesJoinHealth EquityTeam
A nonprofit and independent licensee of the Blue Cross and Blue Shield Association

Support for The Michigan Collaborative for Type 2 Diabetes (MCT2D) is provided by Blue Cross and Blue Shield of Michigan as part of the BCBSM Value Partnerships program.

Although Blue Cross Blue Shield of Michigan and MCT2D work collaboratively, the opinions, beliefs and viewpoints expressed by the author do not necessarily reflect the opinions, beliefs and viewpoints of BCBSM or any of its employees.